Nanohale AG (ETR:FYB) | WebDisclosure

Basculer en Français

9480	Companies
185543	Keywords
117939	Articles
99384	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 06/17/2025 at 07:55, 5 months 18 days ago

EQS-Adhoc: Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth
Formycon AG plans EUR 50 million senior unsecured bond issuance for company growth. Joint Lead Managers: IKB Deutsche Industriebank AG, Pareto Securities AS

Formycon AG Bond Issuance EUR 50 Million Senior Unsecured Joint Lead Managers
BRIEF

published on 06/05/2025 at 06:35, 6 months ago

Lucentis® Biosimilar FYB201/Ranivisio® Gains Approval in Brazil

Formycon AG Retinal Diseases Lucentis® Biosimilar Brazil Approval Biomm Partnership
BRIEF

published on 06/05/2025 at 06:35, 6 months ago

Le biosimilaire Lucentis® FYB201/Ranivisio® obtient l'approbation au Brésil

Formycon AG Maladies De La Rétine Lucentis® Biosimilaire Approbation Du Brésil Partenariat Biomm
PRESS RELEASE

published on 06/05/2025 at 06:30, 6 months ago

Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil
Brazil approves Formycon AG's Lucentis biosimilar FYB201/Ranivisio, marking the beginning of Latin America rollout. Commercial partnership with Biomm established

Formycon AG Lucentis Biosimilar Brazil Approval Biomm Partnership Market Rollout
BRIEF

published on 05/27/2025 at 14:35, 6 months 9 days ago

Formycon et Fresenius Kabi lancent Otulfi™ au Canada

Marché Canadien Soutien Aux Patients Biosimilaire De L'ustekinumab Maladies Auto-immunes Chroniques Thérapies Biologiques
BRIEF

published on 05/27/2025 at 14:35, 6 months 9 days ago

Formycon and Fresenius Kabi Launch Otulfi™ in Canada

Canadian Market Patient Support Ustekinumab Biosimilar Chronic Autoimmune Diseases Biologic Therapies
PRESS RELEASE

published on 05/27/2025 at 14:30, 6 months 9 days ago

Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada
Formycon and Fresenius Kabi announce commercial launch of FYB202/Otulfi ustekinumab biosimilar in Canada, expanding treatment options for chronic autoimmune diseases

Canada Formycon Fresenius Kabi Ustekinumab Biosimilar FYB202/Otulfi
BRIEF

published on 05/19/2025 at 15:05, 6 months 17 days ago

Formycon et Fresenius Kabi obtiennent l'approbation d'interchangeabilité de la FDA pour FYB202/Otulfi®

Approbation De La FDA Formycon Fresenius Kabi Biosimilaires Otulfi®
BRIEF

published on 05/19/2025 at 15:05, 6 months 17 days ago

Formycon and Fresenius Kabi Achieve FDA Interchangeability Approval for FYB202/Otulfi®

FDA Approval Biosimilars Formycon Fresenius Kabi Otulfi®
PRESS RELEASE

published on 05/19/2025 at 15:00, 6 months 17 days ago

Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
Formycon and Fresenius Kabi receive FDA approval for interchangeability of FYB202/Otulfi (ustekinumab-aauz) with Stelara, enhancing patient access to treatment options for inflammatory diseases in the US

FDA Approval Formycon Fresenius Kabi Biologics Interchangeability

Accesswire

Published on 12/05/2025 at 20:25, 44 minutes ago

The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others
Published on 12/05/2025 at 20:15, 54 minutes ago

When Proof Becomes Infrastructure, Markets Rewrite the Story (NASDAQ: SMX)
Published on 12/05/2025 at 19:50, 1 hour 19 minutes ago

Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 1 hour 49 minutes ago

The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 2 hours 24 minutes ago

Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 2 hours 11 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 2 hours 43 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 2 hours 54 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 3 hours 17 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 3 hours 23 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 3 hours 51 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 3 hours 51 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 5 hours 58 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 5 hours 58 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 7 hours 11 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE